Exhibit 10.1NOTE: Certain information indicated with [] in this document has been omitted from this exhibit because it is both (i) not material and (ii)would be competitively harmful if publicly disclosed.MASTER JOINT DEVELOPMENT AGREEMENTThis Master Joint Development Agreement ("Agreement") is between iBio Inc., a Public corporation, with a location at iBio Inc., 600 Madison Ave,Suite 01601 NY, NY 10022-1735 and Beijing CC-Pharming Ltd. of Beijing, China (“CC-Pharming”), a Chinese Corporation with a location at ShunyiDistrict, Beijing, China, 101312, each of the foregoing being individually referred to as a “Party” and collectively as the “Parties”.WHEREAS, iBio and CC-Pharming wish to establish a long-term working relationship for various joint research and development projects(“Projects”) related to the development of various products, with the work for each Project to be described in a separate Statement of Work(“SOW”) agreed by the Parties;WHEREAS, iBio has developed and owns proprietary technology used to produce proteins using proprietary vector systems that supporttransient gene expression and protein production in plants, and iBio has developed and/or acquired additional proprietary biopharmaceuticaltechnology, cGMP manufacturing expertise (“iBio’s Technology”), and a facility design team that provides capabilities for application to thedevelopment of biotherapeutics; andWHEREAS, iBio and CC-Pharming, wish to develop one or more biopharmaceuticals Product(s) (each a “Product”) based on iBio’sproprietary and patented plant-based protein production technology and know-how;WHEREAS, iBio and CC-Pharming wish to develop a long-term, mutually beneficial relationship for the production and sale ofbiopharmaceuticals in China and to form a collaborative business venture to be majority owned and controlled by CC-Pharming and minority ownedby iBio; andNOW, THEREFORE, for good and valuable consideration as stated herein, the sufficiency of which is hereby expressly acknowledged byeach Party, iBio and CC-Pharming agree as follows:1.0Limited Technology License1.1iBio hereby grants to CC-Pharming for the term of this Agreement, a nonexclusive, non- assignable, non-sublicensable, limited right andlicense to use iBio’s Technology in order to manufacture, process, prepare, and obtain regulatory approval for the development andproduction of Product(s) and work to be performed under this Agreement. Each Product will be set forth in a separate Statement of Workin the form set forth in Appendix A, which will be signed by representatives of each Party with signing authority. Each phase of theproject(s) will be subject to the terms and conditions set forth in this Agreement unless otherwise provided for or in a Statement of Work(“SOW”), including but not limited to project purpose, project phases, and a project budget.Master Joint Development Agreement iBio CC-PharmingSource: IBIO, INC., 8-K, 3/13/20201.2No right or license is being conveyed to CC-Pharming to export Products or to otherwise use the Technology in any country other thanChina.1.3iBio will work with CC-Pharming to perform a thorough Manufacturing Development Program based from an initial comprehensive two-day charrette to be held at its subsidiary iBio CDMO LLC facility in Bryan, Texas with the goals of CC-Pharming understanding thedefinitive capital expenditure necessary and initiating a preliminary design for the first Product. iBio will provide an architect, constructionsupervisor, mechanical engineer and process engineer with knowledge of the iBio CDMO facility currently in operation in Bryan, Texas.1.4CC-Pharming hereby expressly acknowledges the validity and highly confidential and proprietary nature of iBio’s Technology andtechnical information, know-how, documents, materials, software, vectors, constructs, trade secrets, and other valuable business orscientific information that iBio will share with CC-Pharming in order to fulfill the purpose of this Agreement, namely, to form a legalstructure for a collaborative business venture in which CC-Pharming and iBio shall share revenue from product sales. iBio’s double-digitpercentage, minority interest in this structure will provide compensation to iBio for providing CC-Pharming with a license to use iBio’sTechnology and enabling know-how and will provide CC-Pharming with ongoing and mutually agreed technology transfer servicesrelevant to the evolving business and Product(s) of the collaborative venture.1.5The parties agree that the first product focus of the joint business collaboration will be a bio-better or bio-similar version of thetherapeutic monoclonal antibody, rituximab. iBio will provide all necessary gene expression and vector technology for the transientexpression and cGMP manufacturing of this protein in plants and will also provide pilot plant design services, construction consulting,product and process development services, training, quality management system design, and clinical planning and regulatory consulting.The tasks to be conducted in the first stage of the joint business collaboration will apply specifically to the rituximab product candidatebut will be applicable, in part, to additional products to be selected by mutual agreement for development, with the timeline for such workto be determined by CC-Pharming.1.5Any milestones or completion dates set forth in a Statement of Work will be estimates only, and are not binding on the Parties.2.0Coordinators and Governance Terms2.1Project Technical Coordinators will be appointed by each the Parties for each Statement of Work. The Project Technical Coordinators willbe responsible for exchanging information with the other Party, coordinating any visits and arranging all other matters pertinent to thatStatement of Work.Master Joint Development Agreement iBio CC-PharmingSource: IBIO, INC., 8-K, 3/13/20202.2Agreement Administration. The Agreement administrator for each Party must be contacted regarding all business-related matters,including any proposed modifications to this Agreement, the phasing plan of the SOW, for each project.An iBio Agreement Administrator is to be named on or before the Effective Date of the First Phase of the SOW.A CC-Pharming Agreement Administrator is to be named on or before the Effective Date of the First Phase of the SOW.2.4Governance Terms2.4.1The Agreement Administrators shall oversee the overall direction and management of this Agreement and to provide guidance anddirection when needed, which agreement shall be unanimous. The responsibilities of the Agreement Administrator for iBio and CC-Pharming will include the following:a)Perform oversight for each of the ongoing projects, per phase, under the SOW’s.b)Agreement on any modifications to the tasks and responsibilities for an ongoing project under the SOW’s, will fallunder the oversight of the Agreement Administrators.c)Neither Agreement Administrator is authorized to modify or change any term or condition of the Agreement or theoverall scope of work for any SOW.d)Review any disputes between or among the Parties, and, if resolution of the dispute cannot be achieved, escalate thedispute to the Designated Executives of iBio and CC-Pharming. “Designated Executive” means the executive designatedby iBio and by CC-Pharming, who will be responsible for general oversight of the Agreement and for resolving issuesthat require escalation under this Agreement. iBio and CC-Pharming shall each inform the other of the name and contactinformation of their respective Designated Executives on or before the Effective Date of the first SOW.2.4.2The Agreement Administrators may agree to change the tasks, task responsibilities and milestones as set forth in a Statement of Work,provided the changes do not alter the overall scope of work in a phase of the SOW, which agreement shall not be unreasonably withheld.Any modifications to the overall scope of work of phase of the SOW must be reduced to writing as an amendment to the SOW and signedby authorized representatives of iBio and CC-Pharming.2.4.3The Agreement Administrators shall meet regularly as required during the term of this Agreement, but at least two (2) times each calendaryear, at a mutually agreeable location, which agreement shall not be unreasonably withheld. The face-to-face meetings may be replacedwith conference calls or video conferences upon request by a Party.2.4.4The Parties shall be responsible for their own respective costs incurred relating to their participation in oversight meetings.Master Joint Development Agreement iBio CC-PharmingSource: IBIO, INC., 8-K, 3/13/20202.5Each Party may change its Agreement Administrators, at any time, with written notice to the other Party.3.0Costs and Expenses3.1Upon execution of this Agreement and acceptance of iBio’s proposal for the development of a Plant-Made Rituximab, and in considerationfor providing the technology transfer contemplated herein, CC-Pharming shall pay iBio [], which shall be paid as follows:3.1.1First payment of [] is required to initiate the project: [].3.1.2Second payment of []. Due upon presentation of the following deliverables:a)Detailed design drawings of the pilot plant;b)Schematic design of the commercial facility;c)Purified antibody for pre-clinical testing and development; andd)The quality management system (QMS) development up to and including governance documents and governance standardoperating procedures (SOP’s).3.1.3Final payment of [], due upon presentation of the following deliverables:a)Detailed Design drawings for the commercial facility;b)Completion of QMS documentation for rituximab including batch records, release documents, and assay SOPs;c)Completion of all training sessions and training documentation;d)Delivery of antibody drug substance for clinical trials; ande)Completion of a chemistry, manufacturing, and controls (CMC) document to support an (investigational new drugapplication (IND) or equivalent.4.0Inventions4.1Inventorship of inventions, developments, or discoveries first conceived or actually reduced to practice under this Agreement(“Agreement Inventions”) will be determined under U.S. Patent Law. All inventions, developments, or discoveries made solely by iBioprior to this Agreement is, and shall be, the sole property of iBio. All inventions, developments, or discoveries made solely by CC-Pharming thereof prior to this Agreement is, and shall be, the sole property of CC-Pharming.4.2All rights to inventions, patentable or non-patentable, made solely by employees of iBio during the term of this Agreement shall belongsolely to iBio. All rights to inventions, patentable or non-patentable, made solely by employees of CC-Pharming during the term of thisAgreement shall belong solely to CC-Pharming. All rights to Agreement Inventions, patentable or non-patentable, made jointly byemployees of iBio and employees of CC-Pharming (“Joint Inventions”) will belong jointly to iBio and CC-Pharming, with inventorshipdetermined as described in 35 U.S.C. § 262 and (Chin Patent Law). The Parties contemplate that each will benefit from Joint Inventions, assuch, iBio will be responsible for direct control over the drafting and prosecution of any patents to Joint Inventions, with copy to CC-Pharming. The parties shall share equally in the costs of patent protection for Joint Inventions.Master Joint Development Agreement iBio CC-PharmingSource: IBIO, INC., 8-K, 3/13/20204.3Each Party shall promptly provide to the other Party a written invention disclosure of each Agreement Invention made by its employeesthat results directly from the present Agreement for worked performed under the SOWs herein. The other Party agrees to delay makingpublic, by publication or otherwise, until the earlier of (a) the first filing of a patent application claiming the Agreement Invention by theInventing Party; or (b) six months after the date the Agreement Invention is disclosed to the other Party; or (c) mutual agreement of theParties that neither will pursue legal protection of an Agreement Invention.4.5Each disclosure shall be held in confidence and not revealed to any third party without the written consent of the other Party. The otherParty must advise the Inventing Party in writing within 60 days of each disclosure to the other Party whether or not the other Party electsto negotiate a license agreement to obtain commercial rights to such Agreement Invention. In the event that the other Party elects tonegotiate for a commercial license to an Agreement Invention, the Parties must initiate negotiation of a license agreement, withnegotiations not to extend beyond ninety (90) days from notice of election without the consent of both Parties. The Parties will negotiatein good faith a license containing reasonable business terms common to the other party’s field of commercial interest and proposedapplication.5.0Copyrights5.1Title to and the right to determine the disposition of any copyrights or copyrightable material first produced or composed in theperformance of this research program (“Copyright Materials”) will remain with the Party whose employees solely created such materials orworks of authorship (the “Creating Party”). Copyright Materials that are jointly created by the Parties shall be jointly owned. Either Partymay license and assign its rights to jointly owned Copyright Materials without the consent of or accounting to the other Party, subject tothe applicable confidentiality obligations set forth in Section 7 of this Agreement and/or a SOW.5.2The Creating Party grants to the other Party a time-limited first right to negotiate a commercial license to use, reproduce, display, andperform commercially valuable Copyright Materials for commercial purposes, and to distribute and/or sublicense such commerciallyvaluable Copyright Materials to third parties. The other Party must advise the Creating Party in writing within sixty (60) days followingdisclosure or delivery of such commercially valuable Copyright Materials to the other Party whether or not the other Party elects tonegotiate a license agreement to obtain commercial rights to the Copyright Materials. In the event that the other Party elects to negotiatefor a commercial license to Copyright Materials, the Parties must initiate negotiation of a license agreement, the negotiations not to extendbeyond ninety (90) days from notice of election without the consent of both Parties. The Parties will negotiate in good faith a licensecontaining reasonable business terms common to the other Party’s field of commercial interest and proposed application.Master Joint Development Agreement iBio CC-PharmingSource: IBIO, INC., 8-K, 3/13/20206.0Term and Termination6.1The term of this Agreement (“Term”) will begin on the date this Agreement is signed by the last signatory (“Effective Date”) and remain ineffect for []; provided, however, that the terms of this Agreement shall remain applicable to any SOW that was executed by the Partiesprior to the expiration or termination of this Agreement but whose period of performance extends beyond the expiration or termination ofthis Agreement.6.2The term of any SOW will be as provided in the Statement of Work.6.3If either Party to this Agreement fails to perform or violates any material obligation of this Agreement, then, upon thirty (30) days writtennotice to the breaching Party specifying such failure or violation, the non-breaching Party may terminate this Agreement without liability,unless: (a) the failure or violation specified in the default notice has been cured within the thirty (30) day notice period; or (b) the failure orviolation reasonably requires more than thirty (30) days to correct, and the breaching Party has begun substantial corrective action toremedy the failure or violation within the thirty (30) day notice period and diligently pursues such action, in which event, termination shallnot be effective unless sixty (60) days has expired from the date of the default notice without such corrective action being completed andthe failure or violation remedied.7.0Confidentiality7.1Except as provided in a Statement of Work and Article 5.3 regarding non-disclosure of Agreement Inventions, any information providedby either Party under this Agreement or under any Statement of Work will be treated as follows.7.2“Confidential Information” includes but is not limited to, technologies, discoveries, inventions, know-how, methods, procedures, tradesecrets, business information and other proprietary intellectual property (“Information”). All such Information is considered by the partiesto be secret and confidential and constitutes valuable commercial assets.7.3Each of the parties agrees that for five (5) years from the date of disclosure, the receiving Party agrees to limit disclosure of the disclosingParty’s Confidential Information to those of the receiving party’s employees and contractors, and employees and contractors of itsSubsidiaries, who have a need to know it, and the receiving Party agrees to use the same care and discretion to avoid disclosure,publication or dissemination outside of those employees and contractors as the receiving Party does with similar information of its ownwhich it does not desire to publish, disclose or disseminate.7.4The receiving Party may disclose Confidential Information if the disclosure is required by law, but the receiving Party must give thedisclosing Party reasonably prior notice to allow the disclosing Party an opportunity to obtain a protective order. The obligations ofArticle 7.3 will not apply to information that is:Master Joint Development Agreement iBio CC-PharmingSource: IBIO, INC., 8-K, 3/13/2020a)already rightfully in the possession of the receiving Party or its Subsidiaries without an obligation of confidence;b)independently developed by the receiving Party of its Subsidiaries as evidenced by written documentation;c)publicly available when received by the receiving Party, or becomes publicly available through no fault of the receivingParty or its Subsidiaries;d)disclosed by the disclosing Party without obligation of confidence; ore)inherently disclosed by the receiving Party or its Subsidiaries in the use, distribution or marketing of any product orservice.7.5The Parties agree that the disclosure of Confidential Information under this Agreement does not limit either Party from assigning orreassigning employees in any way.7.6Confidential Information must be identified as Confidential at the time of disclosure, and all material containing Confidential Informationmust have a restrictive marking. Any Confidential Information disclosed orally or visually must be summarized by the disclosing Party inwriting and the writing must be provided to the receiving Party within twenty (20) days after the disclosure. In the case of inadvertentdisclosure of Confidential information that was not marked as Confidential, the Disclosing Party has ten (10) business days from the timethey discover that the information should have been marked Confidential, to inform the other Party of such a designation, and the partiesagree to retroactively mark any such information as Confidential.7.7The parties agree that limitations on disclosure of Confidential information under section 7.3 shall last 5 years from signing date.8.0Representations, Warranties, Disclaimers and Limitation of Liability8.1ANY PROTOTYPES, MATERIALS, COMPONENT PARTS, DESIGNS, SPECIFICATIONS, KNOW-HOW, PROCEDURES, PROCESSES,DATA, INFORMATION, INVENTIONS AND WORK PERFORMED UNDER THIS AGREEMENT BY EITHER PARTY, ARE PROVIDED“AS IS”, WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. EACH PARTY SPECIFICALLY DISCLAIMS THE IMPLIEDWARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND ANY WARRANTY OFNONINFRINGEMENT OF PATENTS, COPYRIGHTS, OR ANY OTHER INTELLECTUAL PROPERTY RIGHT.8.2EACH PARTY ALSO SPECIFICALLY DISCLAIMS ANY GUARANTEE THAT IT WILL BE ABLE TO SUCCESSFULLY ACHIEVE THEDESIRED RESULTS REGARDING THE WORK UNDER ANY STATEMENT OF WORK, OR THAT ANY PROTOTYPE(S) WHICH MAY BEDEVELOPED PURSUANT TO THIS AGREEMENT WILL MEET ANY DEVELOPMENT OBJECTIVES, OR ANY REQUIREMENTS OFEITHER PARTY. THE FOREGOING NOTWITHSTANDING, EACH PARTY WILL MAKE REASONABLE GOOD FAITH EFFORTS TOCOMPLETE THE ACTIVITIES DESCRIBED IN THE STATEMENTS OF WORK. FAILURE TO ACHIEVE THE DESIRED RESULTS UNDERA STATEMENT OF WORK DOES NOT CONSTITUTE BREACH OF CONTRACT.Master Joint Development Agreement iBio CC-PharmingSource: IBIO, INC., 8-K, 3/13/20208.3Except for claims arising out of Articles 4.3 and 7.0, or as may be set forth in a SOW, neither Party will be liable for any consequentialdamages, lost profits, lost savings, loss of anticipated revenue, or any exemplary, punitive, special or indirect damages, even if advised oftheir possibility.8.4CC-Pharming represents and warranties that it shall maintain all of iBio’s Technology and technical information, how-how, documents,materials, software, vectors, constructs, trade secrets, and other valuable business or scientific information strictly confidential at alltimes, and shall take all steps necessary to safe-guard iBio’s Technology and technical information with reasonable business care and willbe of the same types as currently practiced by iBio to maintain its highly confidential information.8.5Equitable Relief for iBio. CC-Pharming acknowledges that a breach by CC-Pharming of this Agreement shall cause iBio irreparabledamages, for which an award of damages would not be adequate compensation, and agrees that, in the event of a breach or threatenedbreach, iBio will be entitled to seek equitable relief, including a restraining order, injunctive relief, specific performance and any other reliefthat may be available from any court, in addition to any other remedy to which iBio may be entitled at law or in equity. iBio’s equitableremedies are not exclusive but are in addition to all other remedies available at law or in equity.8.6Attorney’s Fees. In the event that any claim, suit, action or proceeding is instituted or commenced by any Party hereto against any otherParty arising out of or related to this Agreement, the prevailing Party will be entitled to recover its reasonable attorneys’ fees, expert fees,expenses and court costs from the non-prevailing Party.9.0General Provisions9.1Independent Contractor. Each Party is an independent contractor. Neither Party is, nor will claim to be, a legal representative, partner,franchisee, agent or employee of the other. Neither Party will assume or create obligations for the other. Each Party is responsible for thedirection and compensation of its employees.9.2Trademarks. Except as otherwise provided herein, this Agreement does not confer any rights to use in advertising, publicity or othermarketing activities any name, trade name, trademark, or other designation of either Party hereto, including any contraction, abbreviation,or simulation of any of the foregoing, without prior written agreement, and each Party agrees not to use or refer to this Agreement or itsterms in any such activities without the express written approval of the other Party.Master Joint Development Agreement iBio CC-PharmingSource: IBIO, INC., 8-K, 3/13/20209.3Publication. iBio and CC-Pharming jointly, may publish and present technical presentations subject to Articles 5.2, 7.0 and this Article 9.2.9.4Notice. All notices shall be in writing and shall be valid and sufficient if sent by: (a) registered or certified mail, return receipt required,postage prepaid; (b) by facsimile (provided the receipt of the facsimile is evidenced by a printed record of completion of transmission); or(c) by express mail or courier service providing a receipt of delivery. Notice shall be effective upon receipt. The notices shall be addressedto:iBio, Inc.Beijing CC-Pharming Ltd.Robert L. ErwinKevin Y. WangPresidentChairman600 Madison Ave, Suit 1601Shunyi DistictNew York, NY 10022-1737 U.S.ABeijing, China, 101312Attn: Rober L. ErwinAttn: Kevin Y. WangEither Party may change its address by a notice given to the other Party in the manner set forth above.9.5Force Majeure. Neither Party shall be liable for any failure or delay in the performance of its obligations under this Agreement if suchfailure or delay is due to acts of God, acts of the other Party, fire, flood, natural catastrophe, acts of any government or of any civil ormilitary authority, national emergencies, riots, war, insurrection, strikes, or any occurrence beyond the reasonable control of such Party.9.6Export Restrictions. Each Party agrees to comply and to reasonably assist the other in complying with applicable government export andimport laws and regulations. Further, each Party agrees that unless authorized by applicable government license or regulation, includingbut not limited to both US and China authorization, both Parties will not directly or indirectly export or re-export, at any time, anytechnology, software and/or commodities furnished or developed under this or any other, Agreement between the Parties, or its directproduct, to any prohibited country (including release of technology, software and/or commodities to nationals, wherever they may belocated, of any prohibited country) as specified in applicable export, embargo, and sanctions regulations. This section will survive aftertermination or expiration of this Agreement and will remain in effect until fulfilled.9.7No Implied Licenses. Except as expressly set forth in this Agreement, no license is granted, either directly or indirectly, by implication orestoppel or otherwise, to either Party under any patent, copyright or other intellectual property right of the other Party.9.8Assignment. Neither Party may assign its rights or delegate any of its duties under this Agreement without the prior written consent ofthe other Party. Any unauthorized assignment of this Agreement is void.9.9Intent. Neither Party relies on any promises, inducements, representations made by the other, or expectations of more business dealingsexcept as expressly provided in this Agreement. This Agreement accurately states the Parties’ agreement.Master Joint Development Agreement iBio CC-PharmingSource: IBIO, INC., 8-K, 3/13/20209.10Power to Enter Agreement. Each Party represents that it has, or will have, in place appropriate agreements with its employees or otherswhose services the Party may require, sufficient to enable such Party to comply with all the provisions of this Agreement.9.11Independent Parties. Each Party may have similar agreements with others, and may design, develop, manufacture, acquire or marketcompetitive products and services, and conduct its business in whatever way it chooses. Each Party will independently establish pricesand terms for its products and services.9.12Severability. If any provision of this Agreement is held to be invalid, illegal or unenforceable, the validity, legality and enforceability of theremaining provisions shall in no way be affected or impaired thereby so long as the intent of the Parties can be preserved.9.13Governing Law. This Agreement is governed by the laws of the State of Texas, without regard to the conflict of laws provisions thereof.Any proceedings to resolve disputes relating to this Agreement shall be brought only in the State of Texas and in a U.S. federal court ifthere is jurisdiction. The United Nations’ Convention on International Sales of Goods does not apply.9.14Survival. Any rights and obligations which by their nature survive and continue after any expiration or termination of this Agreementshall survive and continue and shall bind the Parties and their successors and assigns, until such obligations are fulfilled.9.15No Oral Modifications. Any amendment or modification of this Agreement shall be in writing and shall be signed by authorizedrepresentatives of the Parties. No approval, consent or waiver will be enforceable unless signed by the granting Party. Failure to insist onstrict performance or to exercise a right when entitled does not prevent a Party from doing so later for that breach, or a future breach.9.16Incorporation. This Agreement, Appendix A and SOW’s added as Appendix A-x (where x is the sequential number of the respectivelyadded SOW’s) are the complete and exclusive agreement between the Parties regarding the subject matter hereof and supersedes anyprior oral or written communications or understandings between the parties related to the subject matter hereof.9.17Independent Judgment. The Parties acknowledge that: (a) they had read this Agreement; (b) they understand the terms and conditions ofthis Agreement; (c) they have had the opportunity to seek legal counsel and advice; (d) are of equal bargaining power; and (e) they haverelied on their own judgment in entering into this Agreement.Signature Page to FollowMaster Joint Development Agreement iBio CC-PharmingSource: IBIO, INC., 8-K, 3/13/2020By signing below, the parties agree to the terms of this Agreement.iBio Inc.Beijing CC-Pharming Ltd./s/ Robert L. Erwin/s/ Kevin Yueju WangName: Robert L ErwinName: Kevin Yueju WangTitle: PresidentTitle: ChairmanDate: August 07, 2018Date: August 08, 2018Master Joint Development Agreement iBio CC-PharmingSource: IBIO, INC., 8-K, 3/13/2020APPENDIX A-1Proposal to Beijing CC-Pharming Ltd.Development of a Plant-Made RituximabPrepared by iBio, Inc.for Beijing CC-Pharming Ltd., Beijing, ChinaFebruary 24, 2018[]Project Agreement AdministratorsFor iBio: Robert L. ErwinFor CC-Pharming: Kevin Y. WangBy signing below, the parties agree to the terms of this Statement of Work.IBioCC-Pharming/s/ Robert L. Erwin/s/ Kevin Yueju WangName: Robert L. ErwinName: Kevin Yueju WangTitle: PresidentTitle: ChairmanDate: August 7, 2018Date: August 8, 2018Master Joint Development Agreement iBio CC-PharmingSource: IBIO, INC., 8-K, 3/13/2020